Drug Development Tool Qualification: US FDA Offers Three-Step Review Process
Executive Summary
FDA's proposed review timeline to qualify biomarkers, clinical outcome assessments, and animal models can actually be pretty quick – assuming submissions clear the initial "reviewability" hurdle.
You may also be interested in...
US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.
Evolution In Clinical Outcome Assessments Reflected In US FDA’s Revised Gastroparesis Guidance
Agency recommends an anchor-based approach to statistical analyses of drug effects on core signs and symptoms.
'Huge Need' For Neurotoxicity Biomarkers In Drug Development, FDA's Woodcock Says
"Perfect storm" makes it difficult to develop safety biomarkers, Woodcock tells US FDA workshop, citing lack of body charged with developing them and greater evidence required for their qualification.